Art Bell’s show “Midnight in the Desert” from October 22, 2015, began with Art discussing a recent unsettling event where shots were fired near his studio, causing distress for him and his family. Local neighbors confirmed hearing the shots, and the police investigated the situation. Additionally, Art’s website, Artbell.com, was the target of a denial-of-service attack. Art then transitioned into his main discussion, emphasizing a significant recent discovery: the potential for an alien megastructure around a distant star, an idea that scientists, including NASA sources, were entertaining with a 50% probability. Art underscored the gravity of this revelation, especially considering how unlikely it was that NASA would attribute such a phenomenon to extraterrestrial life. He expanded on the implications of this discovery and shared that SETI had redirected its telescopes to focus on the star in question, looking for signs of intelligent life.
After the introduction, Art welcomed his guest, Douglas Mulhall, a specialist in nanotechnology. They discussed the potential for nanomedicine to revolutionize healthcare, including examples like Cuba’s success in using nanoparticles to create an immune response that helped eradicate bacterial meningitis. Mulhall explained that nanotechnology had the potential to target diseases like cancer and heart disease much more precisely than traditional medicine. Despite skepticism about the affordability of nanomedicine, especially due to resistance from big pharmaceutical companies, Mulhall remained hopeful that the emerging competition from biotech startups would drive innovation and lower costs.
The conversation highlighted both the current state of nanomedicine and its future potential, with a focus on the importance of overcoming institutional resistance. Art voiced concerns about how the high demand for life-extending or life-saving treatments could lead to price gouging, but Mulhall remained optimistic about the ability of nanotechnology to make medicine more affordable. They also touched on the impact of global regulatory differences on the availability of treatments.
Art and Douglas Mulhall continued discussing the profound advancements in nanotechnology, particularly in the field of medicine. Mulhall shared a story from Cuba, where in the early 1980s, researchers developed a vaccine for bacterial meningitis using nanoparticles, long before the rest of the world was familiar with the concept. This Cuban innovation managed to virtually eliminate the disease from the country and later in places like Brazil and New Zealand. Mulhall explained how these nanoparticles, once considered waste products by scientists, were actually crucial tools that could be programmed to fight diseases. The key challenge was isolating and concentrating the correct particles to reintroduce them into the body for an immune response.
The conversation shifted to how these advancements could have broader applications, such as in heart disease and cancer treatment, where targeting specific areas with nanoparticle-based medicines could drastically reduce side effects and increase effectiveness. Mulhall highlighted the need for precise targeting, which is becoming increasingly possible through advancements in antibody technology. He explained that while traditional drugs often work systemically, impacting the entire body and causing numerous side effects, nanomedicine has the potential to deliver treatments directly to the source of the problem, drastically improving outcomes.
Art, ever the skeptic, brought up the concern that pharmaceutical giants might resist these technologies because they threaten the profitability of their existing drug lines. Mulhall acknowledged this institutional inertia but countered that new biotech companies and medical device firms, which don’t have the same financial investments in old treatments, are pushing forward with these innovations. He pointed to examples from India, where the country is rejecting certain patent restrictions and moving forward with affordable drug production, creating a competitive market that could drive down prices globally.
As the conversation progressed, Art raised a concern about the affordability of nanomedicine and whether it could realistically become accessible to the general population, given the influence of large pharmaceutical companies. Mulhall acknowledged the challenge, admitting that the pharmaceutical industry might resist due to the threat to their current profit models. However, he remained hopeful, pointing out that smaller biotech companies and global markets like India were already adopting nanotechnologies and moving toward more affordable treatments. He emphasized that technological advances, particularly in antibody-based therapies combined with nanoparticles, are progressing rapidly and have already begun to make their way through regulatory processes in Europe and the United States. The acceleration of approval processes by agencies like the FDA, particularly for life-threatening conditions, is paving the way for faster adoption of these new treatments.
Art then brought up the issue of cost, citing examples of drugs with astronomical prices, like a recent cystic fibrosis drug that cost $259,000 annually. Mulhall agreed that this was a serious problem but reiterated that the nature of nanomedicine—being more targeted and reducing the need for broad, systemic treatments—could ultimately reduce overall healthcare costs by minimizing side effects and lowering the need for extensive medical oversight. He highlighted that while we are still in the early stages, the potential for nanomedicine to revolutionize healthcare and make treatments more affordable is real.
Art, remaining cautiously skeptical, pressed further, asking if Mulhall truly believed that these advancements would become affordable to the masses. Mulhall responded by discussing initiatives like the “Nanomedicine for All” campaign, which aims to bring these therapies to clinical trials and eventually to market by 2020, specifically focusing on diseases like heart disease. He acknowledged that the road ahead would be difficult, with pushback from large institutions, but he firmly believed that the benefits of nanomedicine—precise targeting, fewer side effects, and lower costs—would eventually win out.
With the conversation winding down, Art reflected on the revolutionary potential of nanotechnology in various fields, from healthcare to energy production. Mulhall, in turn, expressed his excitement for the future of nanotechnology and its potential to transform not just medicine but industries worldwide. Their discussion ended with Mulhall reiterating the importance of public and private sector cooperation in advancing these technologies, and Art thanking him for sharing his expertise.